Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.

Published byJayson Norton Modified over 6 years ago

Similar presentations

Presentation on theme: "Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis."— Presentation transcript:

1 Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults  Amy S. Paller, MS, MD, Wynnis L. Tom, MD, Mark G. Lebwohl, MD, Robin L. Blumenthal, PhD, Mark Boguniewicz, MD, Robert S. Call, MD, Lawrence F. Eichenfield, MD, Douglass W. Forsha, MD, William C. Rees, MD, Eric L. Simpson, MD, Mary C. Spellman, MD, Linda F. Stein Gold, MD, Andrea L. Zaenglein, MD, Matilda H. Hughes, CCRA, Lee T. Zane, MD, Adelaide A. Hebert, MD  Journal of the American Academy of Dermatology  Volume 75, Issue 3, Pages e6 (September 2016) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Atopic dermatitis. Enrollment, randomization, treatment, and follow-up. BSA, Body surface area; ISGA, Investigator's Static Global Assessment. Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Atopic dermatitis (AD). Efficacy analysis. In studies AD-301 and AD-302, a greater proportion of crisaborole-treated patients achieved success in Investigator's Static Global Assessment (ISGA) score by day 29 (A). In addition, crisaborole-treated patients achieved success in ISGA score earlier than vehicle-treated patients as analyzed by Kaplan-Meier analysis (pooled) (B). A greater proportion of crisaborole-treated patients achieved an ISGA score of clear (0) or almost clear (1) by day 29 (C). D and E, Photographs demonstrate success in ISGA score at day 29. Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Atopic dermatitis (AD). Improvements in pruritus. In a pooled analysis of studies AD-301 and AD-302, a greater percentage of crisaborole-treated patients achieved improvement in pruritus at the earliest evaluation and throughout treatment compared with vehicle-treated patients. Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Atopic dermatitis (AD). Improvement in signs of AD. In pooled analysis of AD-301 and AD-302, comparison of crisaborole-treated with vehicle-treated patients at day 29 revealed a greater proportion of crisaborole-treated patients achieved improvement in signs of AD (A), with greater mean reductions in severity from baseline (B). Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

6 Supplementary Fig 1 Atopic dermatitis (AD). Study design and treatment. Key screening criteria, patient enrollment, randomization, and assessments. AD, Atopic dermatitis; BID, twice daily; BSA, body surface area; ECG, electrocardiography; ISGA, Investigator's Static Global Assessment; TCI, topical calcineurin inhibitor; TCS, topical corticosteroid. *Proprietary vehicle developed by Anacor Pharmaceuticals, Inc. Journal of the American Academy of Dermatology  , e6DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis."

Similar presentations

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Eucrisa™ - Crisaborole

Eucrisa™ - Crisaborole
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata  Yong Hyun Jang, MD,

Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata  Yong Hyun Jang, MD,
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.

Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.
A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity  Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity  Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Similar presentations

Ads by Google